

February 28, 1967

Dr. T. P. S. Watts
Geigy Pharmaceuticals
Ardsley, New York 10502

Dear Paddy,

It was a pleasure having lunch with you today. As we discussed, enclosed is a revised ST-155 protocol. Would you please send me your anxiety scale and any other suggested forms for use in this study. As soon as I have reviewed these scales I will send you copies, as we plan to use them. (May I remind you to send me the Sugerman and your own ST-155 data?)

May I remind you again to arrange to send me capsules of Tofranil, either 50 or 25 mg each for our narcotic antagonism study. A proposed protocol is enclosed. This has not yet been approved. It may require some modification, but it should be sufficient for your records.

I am also pleased to confirm our interest in kete-imipramine (GP 35259) both for its neurophysiologic profile and for its clinical antidepressant activity in comparison to Tofranil.

My best regards.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp